RU1811847C - Method of destructive renal tuberculosis treatment - Google Patents
Method of destructive renal tuberculosis treatmentInfo
- Publication number
- RU1811847C RU1811847C SU4380211A RU1811847C RU 1811847 C RU1811847 C RU 1811847C SU 4380211 A SU4380211 A SU 4380211A RU 1811847 C RU1811847 C RU 1811847C
- Authority
- RU
- Russia
- Prior art keywords
- days
- destructive
- patient
- treatment
- amniocene
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 7
- 230000001066 destructive effect Effects 0.000 title claims description 6
- 206010038534 renal tuberculosis Diseases 0.000 title 1
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 6
- 239000000814 tuberculostatic agent Substances 0.000 claims abstract description 5
- 230000004936 stimulating effect Effects 0.000 claims abstract description 3
- 210000003734 kidney Anatomy 0.000 claims description 5
- 230000000035 biogenic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 5
- 230000001549 tubercolostatic effect Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- PSWOBQSIXLVPDV-CXUHLZMHSA-N chembl2105120 Chemical compound C1=C(O)C(OC)=CC(\C=N\NC(=O)C=2C=CN=CC=2)=C1 PSWOBQSIXLVPDV-CXUHLZMHSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относитс к медицине, в частности к фтизиоурологии, и может быть использовано при стационарном консервативном лечении больных туберкулезом. Способ заключаетс в том, что больному кроме туберкулостатических препаратов подкожно ввод т амниоцен в количестве 3,0 мл один раз в три дн на прот жении 12-15 дней. Изобретение направлено на сокращение сроков лечени за счет стимулировани естественной .иммунореактивности организма больного..The invention relates to medicine, in particular to phthisiourology, and can be used in inpatient conservative treatment of tuberculosis patients. The method consists in the fact that in addition to tuberculostatic preparations, the patient is injected subcutaneously with amniocene in an amount of 3.0 ml once every three days for 12-15 days. The invention is aimed at reducing treatment time by stimulating the natural. Immunoreactivity of the patient’s body ..
Description
Изобретение относитс к медицине, в частности к фтизиоурологии, и может быть использовано при лечении больных нефро- туберкулезом.The invention relates to medicine, in particular to phthisiourology, and can be used in the treatment of patients with nephro-tuberculosis.
Цель изобретени - сокращение сроков лечени за счет стимул ции естественной иммунореактивности организма.The purpose of the invention is to reduce the duration of treatment by stimulating the body's natural immunoreactivity.
Использование предлагаемого способа обеспечивает сокращение сроков стационарного лечени деструктивного туберкулеза почек до 10,16±0,26 недель по сравнениюс 22,32 ±0,32 недель при использовании способа-прототипа, т.е. примерно в 2 раза, что значительно сокращает расходы на содержание больных с стационаре. При этом врем прекращени бактериовы- делени составл ет 4,2 ±0,10 недель против 12,0 ±0.50, что в 3 раза меньше. Врем ремиссии заболевани увеличиваетс в 2 раза с 26,26 ±0,42 до 55,б± 0,70. Сокраа1ение сроков лечени в стационаре в среднем на 12 недель существенно снижаетUsing the proposed method provides a reduction in the time of inpatient treatment of destructive tuberculosis of the kidneys to 10.16 ± 0.26 weeks compared to 22.32 ± 0.32 weeks when using the prototype method, i.e. about 2 times, which significantly reduces the cost of maintaining patients with a hospital. At the same time, the termination of bacterial excretion is 4.2 ± 0.10 weeks versus 12.0 ± 0.50, which is 3 times less. The time of disease remission is doubled from 26.26 ± 0.42 to 55, b ± 0.70. Reducing the duration of treatment in hospital by an average of 12 weeks significantly reduces
количество введенных больному туберкулостатических препаратов, вызывающих значительные побочные влени . the amount of tuberculostatic drugs administered to the patient, causing significant side effects.
Сущность изобретени состоит в том, что по способу лечени деструктивного туберкулеза почек, включающему туберкулостатических средств в сочетании с биогенными стимул торами, в качестве биостимул тора используют амниоцен, который ввод т подкожно по 3 мл один раз в три дн в течение 12-15 дн. Изобретение осуществл етс следующим образом. После установлени диагноза - прогрессирующий деструктивный туберкулез почек и определеннее помощью комплекса иммунологиче- ских тестов состо ние Т-и В-систем иммунитета провод т клинико-иммунологи- ческое сопоставление, позвол ющее объективно оценить взаимосв зь деструктивного процесса в почках с выраженностью вторичного иммунодефицита.The essence of the invention is that according to the method of treating destructive tuberculosis of the kidneys, including tuberculostatic agents in combination with biogenic stimulants, amniocene is used as a biostimulant, which is administered subcutaneously in 3 ml once every three days for 12-15 days. The invention is carried out as follows. After the diagnosis is established, progressive destructive tuberculosis of the kidneys and, more accurately, using the complex of immunological tests, the state of the T and B immunity systems is carried out by a clinical and immunological comparison, which makes it possible to objectively evaluate the relationship of the destructive process in the kidneys with the severity of secondary immunodeficiency.
(/(/
сwith
соwith
оо vjoo vj
Больному ввод т туберкулостатические препараты, например, в следующем наборе: стрептомицин до 1 г в сутки, тубазид или фтивазид до 1 г в сутки, рифадин до 1 г в сутки, этамбутол до 1 г в сутки в комплексе с витаминотерапией и препаратами коры надпочечников. На фоне проводимого лечени больному подкожно ввод т амниоцен в количестве 3 мл один раз в три дн в течение 12-15 дн. В особо т желых случа х заболевани через 2 недели курс инъекций амнио- цена повтор ют.Tuberculostatic drugs are administered to a patient, for example, in the following kit: streptomycin up to 1 g per day, tubazide or phtivazide up to 1 g per day, rifadine up to 1 g per day, ethambutol up to 1 g per day in combination with vitamin therapy and adrenal cortex drugs. Against the background of the treatment, the patient is injected subcutaneously with amniocene in an amount of 3 ml once every three days for 12-15 days. In especially severe cases of the disease, after 2 weeks, the amniocene injection course is repeated.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU4380211 RU1811847C (en) | 1988-01-04 | 1988-01-04 | Method of destructive renal tuberculosis treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU4380211 RU1811847C (en) | 1988-01-04 | 1988-01-04 | Method of destructive renal tuberculosis treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU1811847C true RU1811847C (en) | 1993-04-30 |
Family
ID=21356380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU4380211 RU1811847C (en) | 1988-01-04 | 1988-01-04 | Method of destructive renal tuberculosis treatment |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU1811847C (en) |
-
1988
- 1988-01-04 RU SU4380211 patent/RU1811847C/en active
Non-Patent Citations (1)
| Title |
|---|
| Мочалова М.П. Раннее вы вление, диагностика, клиника и лечение туберкулеза мочеполовой системы. Методические рекомендации М.: 1976, с. 29-30. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Von Euler et al. | Present status of diagnosis and treatment of pheochromocytoma | |
| OSEI et al. | Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones | |
| Govier et al. | Experience with triple-drug therapy in a pharmacological erection program | |
| US4565805A (en) | Pharmaceutical preparation for the treatment of peptic ulcer | |
| Klein et al. | Thymoma and polymyositis: onset of myasthenia gravis after thymectomy: report of two cases | |
| Ashworth et al. | Some effects of BZ-55 (carbutamide) on the growth of the islets of Langerhans | |
| JPH0776179B2 (en) | Composition for treating diseases including immunological factors | |
| EP0346297A1 (en) | A preparation for topical use in the therapeutic treatment of impotentia coeundi | |
| Smallwood | Effect of intravenous calcium administration on gastric secretion of acid and pepsin in man | |
| Bluntschli, HJ*** & Goetz | The effect of a new sympathicolytic drug (dihydroergocornine) on the blood-pressure with special reference to hypertension | |
| RU1811847C (en) | Method of destructive renal tuberculosis treatment | |
| RU2050855C1 (en) | Method of pathogenetic treatment of patients suffering from infiltrative pulmonary tuberculosis | |
| HOWARD et al. | Effects of pituitary adrenocorticotropic hormone (ACTH) on the hypersensitive state | |
| Teisinger | Biochemical responses to provocative chelation by edetate disodium calcium | |
| JP2930362B2 (en) | A therapeutic agent for a sensitized T cell-related disease | |
| RU2063751C1 (en) | Medicinal agent stimulating granulocyte hemopoiesis stem at cytostatic hypoplasia of bone marrow | |
| CHENEY et al. | A possible relationship of pancreatic insufficiency to Addison-Biermer (pernicious) anemia | |
| RU2016580C1 (en) | Method of curing complicated rheumatoid arthritis | |
| RU2370264C2 (en) | Method of organism disintoxication in surgery of locally advanced hypernephroid cancer | |
| Grob | Muscular disease | |
| RU2018320C1 (en) | Method for treatment of juvenile rheumatic arthritis | |
| SU1560214A1 (en) | Method of treating phantom limb pain | |
| RU2146884C1 (en) | Method for treating the cases of diffuse toxic goiter | |
| Belknap | Modern Trends in the Treatment of Lead Poisoning: A Review of the Literature on the Use of Edathamil Calcium-Disodium | |
| SU1076124A1 (en) | Method of treatment of acute pancreatitis |